MONOCLONAL ANTIBODIES TARGETING CGRP IN MIGRAINE: CURRENT PERSPECTIVES AND CLINICAL GUIDELINES

Aim: This review aims to explore the clinical relevance and therapeutic potential of monoclonal antibodies targeting the calcitonin gene-related peptide (CGRP) pathway in the preventive treatment of migraine. Emphasis is placed on their mechanism of action, efficacy, and safety as demonstrated in clinical trials, as well as on their practical implementation in routine care. By examining current evidence and real-world application, the review seeks to inform clinicians about the benefits and appropriate use of anti-CGRP monoclonal antibodies in patients with disabling migraine. Methods: We conducted a comprehensive literature search in April and May 2025 using the PubMed and Google Scholar databases. The search included peer-reviewed articles published between 2015 and 2025, with a focus on studies investigating monoclonal antibodies and geptans used in the treatment of migraine. We prioritized original research involving human subjects and excluded unpublished abstracts and conference proceedings. Only articles available in English and Polish were considered. Results: Recent studies confirm the sustained safety and effectiveness of all four CGRP monoclonal antibodies, supporting earlier access due to their good tolerability, reduced migraine frequency, and improved quality of life. Conclusions: We should increase the awareness among specialists about the effectiveness and safety of anti-CGRP monoclonal antibodies so that more patients have the opportunity to benefit from treatment.